{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:18:09Z","timestamp":1784297889054,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.clinre.2021.101814","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T14:33:27Z","timestamp":1632839607000},"page":"101814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history"],"prefix":"10.1016","volume":"46","author":[{"given":"Junjun","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongliang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2021.101814_bib0001","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2021.101814_bib0002","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2021.101814_bib0003","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1586\/17474124.2015.1028363","article-title":"The evolving epidemiology of hepatocellular carcinoma: a global perspective","volume":"9","author":"Wallace","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2021.101814_bib0004","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1067\/j.cpradiol.2015.04.004","article-title":"Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment, and treatment","volume":"44","author":"Clark","year":"2015","journal-title":"Curr Probl Diagn Radiol"},{"key":"10.1016\/j.clinre.2021.101814_bib0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.semdp.2016.12.011","article-title":"The diagnosis and treatment of hepatocellular carcinoma","volume":"34","author":"Hartke","year":"2017","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.clinre.2021.101814_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218165","article-title":"Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma","volume":"21","author":"Chang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinre.2021.101814_bib0007","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clinre.2021.101814_bib0008","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/modpathol.2016.111","article-title":"Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization","volume":"29","author":"Rhee","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clinre.2021.101814_bib0009","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/liv.12844","article-title":"TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma","volume":"35","author":"Sciarra","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2021.101814_bib0010","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.2217\/fon-2018-0136","article-title":"DEB-TACE: a standard review","volume":"14","author":"Melchiorre","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.clinre.2021.101814_bib0011","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jhep.2015.02.010","article-title":"Transarterial chemoembolization: modalities, indication, and patient selection","volume":"62","author":"Sieghart","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2021.101814_bib0012","doi-asserted-by":"crossref","first-page":"374","DOI":"10.5582\/bst.2019.01153","article-title":"The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis","volume":"13","author":"Han","year":"2019","journal-title":"Biosci Trends"},{"key":"10.1016\/j.clinre.2021.101814_bib0013","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.clinre.2021.101814_bib0014","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12957-018-1368-8","article-title":"CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study","volume":"16","author":"Wu","year":"2018","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.clinre.2021.101814_bib0015","first-page":"7456","article-title":"Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres((R)) microspheres and conventional transarterial chemoembolization as first-line treatment in hepatocellular carcinoma patients","volume":"11","author":"Ma","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.clinre.2021.101814_bib0016","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4103\/1319-3767.157571","article-title":"Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma","volume":"21","author":"Arabi","year":"2015","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.clinre.2021.101814_bib0017","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12876-018-0848-1","article-title":"Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma","volume":"18","author":"Liu","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.clinre.2021.101814_bib0018","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jhep.2012.07.017","article-title":"Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma","volume":"57","author":"Song","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2021.101814_bib0019","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.crad.2018.12.008","article-title":"Time-to-progression following conventional compared with drug-eluting-bead transcatheter arterial chemoembolisation in patients with large hepatocellular carcinoma","volume":"74","author":"Ou","year":"2019","journal-title":"Clin Radiol"},{"key":"10.1016\/j.clinre.2021.101814_bib0020","doi-asserted-by":"crossref","first-page":"CR189","DOI":"10.12659\/MSM.881714","article-title":"Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin\/lipiodol (cTACE)","volume":"17","author":"Wiggermann","year":"2011","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.clinre.2021.101814_bib0021","doi-asserted-by":"crossref","first-page":"e15314","DOI":"10.1097\/MD.0000000000015314","article-title":"Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: a comparison of efficacy and safety","volume":"98","author":"Li","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.clinre.2021.101814_bib0022","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2015.01.028","article-title":"Clinical trial watch: reports from the AASLD Liver Meeting(R), Boston, November 2014","volume":"62","author":"Londono","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2021.101814_bib0023","first-page":"1150","article-title":"Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres(R) microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma","volume":"24","author":"Zhao","year":"2019","journal-title":"J BUON"},{"key":"10.1016\/j.clinre.2021.101814_bib0024","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.clinre.2021.101814_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165611","article-title":"Hypoxia and HIF signaling: one axis with divergent effects","volume":"21","author":"Corrado","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinre.2021.101814_bib0026","first-page":"96","article-title":"Transcatheter embolization therapy in liver cancer: an update of clinical evidences","volume":"27","author":"Wang","year":"2015","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.clinre.2021.101814_bib0027","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/01.RVI.0000228416.21560.7F","article-title":"Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization","volume":"17","author":"Lewis","year":"2006","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.clinre.2021.101814_bib0028","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12094-018-1902-8","article-title":"CalliSpheres(R) drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study","volume":"21","author":"Zhang","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clinre.2021.101814_bib0029","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1186\/s12885-018-4566-4","article-title":"Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres(R) beads in Chinese hepatocellular carcinoma patients","volume":"18","author":"Zhou","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinre.2021.101814_bib0030","article-title":"Glycosylation in the Tumor Microenvironment: implications for Tumor Angiogenesis and Metastasis","volume":"8","author":"Chandler","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.clinre.2021.101814_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092347","article-title":"Liver zonation in health and disease: hypoxia and hypoxia-inducible transcription factors as concert masters","volume":"20","author":"Kietzmann","year":"2019","journal-title":"Int J Mol Sci"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740121001923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740121001923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:31:47Z","timestamp":1761895907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740121001923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2210740121001923"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2021.101814","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2021.101814","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101814"}}